A6.21 NF-κB-inducing kinase (NIK) is expressed in synovial endothelial cells in early arthritis patients and correlates with markers of inflammation

Autor: P.P. Tak, C van der Leij, Kpm van Zoest, M. Maas, Mjh de Hair, IY Choi, Sander W. Tas, AR Noort, KI Maijer, Danielle M. Gerlag

Publikováno v: Annals of the Rheumatic Diseases. 74:A64.1-A64

Background and objectives The NF-κB family of transcription factors is strongly involved in synovial inflammation. We have previously shown that NF-κB-inducing kinase (NIK) is a key regulator of inflammation-induced angiogenesis in rheumatoid arthr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::025bccfdfc9eeb6057a89758843d9bc4
https://doi.org/10.1136/annrheumdis-2015-207259.147

Synovial gene signatures associated with the development of rheumatoid arthritis in at risk individuals: A prospective study.

Autor: de Jong TA; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands., de Hair MJH; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands., van de Sande MGH; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands., Semmelink JF; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands., Choi IY; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands., Gerlag DM; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands; UCB Pharma, Slough SL1 3XE, UK., Tak PP; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands; Candel Therapeutics, Needham, MA, USA; Internal Medicine, Cambridge University, Cambridge, CB2 1TN, UK., van Baarsen LGM; Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute, Amsterdam, Netherlands; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands. Electronic address: e.g.vanbaarsen@amsterdamumc.nl.

Publikováno v: Journal of autoimmunity [J Autoimmun] 2022 Dec; Vol. 133, pp. 102923. Date of Electronic Publication: 2022 Oct 06.

Current Smoking Negatively Affects the Response to Methotrexate in Rheumatoid Arthritis in a Dose-responsive Way, Independently of Concomitant Prednisone Use.

Autor: Safy-Khan M; M. Safy-Khan, MD, P.M. Welsing, PhD, J.M. van Laar, MD, PhD, Professor, J.W. Jacobs, MD, PhD, Associate Professor, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University., de Hair MJH; M.J. de Hair, MD, PhD, Novartis Pharma BV, the Netherlands., Welsing PMJ; M. Safy-Khan, MD, P.M. Welsing, PhD, J.M. van Laar, MD, PhD, Professor, J.W. Jacobs, MD, PhD, Associate Professor, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University., van Laar JM; M. Safy-Khan, MD, P.M. Welsing, PhD, J.M. van Laar, MD, PhD, Professor, J.W. Jacobs, MD, PhD, Associate Professor, Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University., Jacobs JWG

Publikováno v: The Journal of rheumatology [J Rheumatol] 2021 Oct; Vol. 48 (10), pp. 1504-1507. Date of Electronic Publication: 2021 Feb 01.

Effectiveness and safety over 3 years after the 2-year U-Act-Early trial of the strategies initiating tocilizumab and/or methotrexate.

Autor: Verhoeven MMA; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Tekstra J; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Welsing PMJ; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Pethö-Schramm A; F. Hoffmann-La Roche, Basel, Switzerland., Borm MEA; Roche Nederland BV, Woerden., Bruyn GAW; Department of Rheumatology, MC Group, Lelystad., Bos R; Department of Rheumatology, Medical Center Leeuwarden, Leeuwarden., Griep EN; Department of Rheumatology, Antonius Hospital, Sneek., Klaasen R; Department of Rheumatology, Meander Medical Center, Amersfoort, The Netherlands., van Laar JM; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Lafeber FPJG; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Bijlsma JWJ; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., de Hair MJH; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Jacobs JWG; Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

Publikováno v: Rheumatology (Oxford, England) [Rheumatology (Oxford)] 2020 Sep 01; Vol. 59 (9), pp. 2325-2333.

Effect on efficacy and safety trial outcomes of also enrolling patients on ongoing glucocorticoid therapy in rheumatoid arthritis clinical trials of tocilizumab or adalimumab or methotrexate monotherapy.

Autor: Safy-Khan M; Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands marysafy@hotmail.com., Jacobs JWG; Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands., de Hair MJH; Novartis Pharma BV, Amsterdam, The Netherlands., Welsing PMJ; Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands., Edwardes MD; Everest Clinical Research Canada, Markham, Ontario, Canada., Teitsma XM; F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland., Luder Y, Devenport J; F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland., van Laar JM; Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands., Pethoe-Schramm A; F Hoffmann-La Roche AG, Basel, Basel-Stadt, Switzerland., Bijlsma JWJ; Department of Rheumatology and Clinical Immunology, UMC Utrecht, Utrecht, The Netherlands.

Publikováno v: Annals of the rheumatic diseases [Ann Rheum Dis] 2020 Apr; Vol. 79 (4), pp. 460-463. Date of Electronic Publication: 2020 Feb 07.